<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Publishing DTD v3.0 20130521//EN" "http://dtd.nlm.nih.gov/publishing/3.0/journalpublishing3.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="3.0" article-type="research-article">
<front>
<journal-meta>
<journal-id journal-id-type="nlm-ta">J Oral Maxillofac Res</journal-id>
<journal-id journal-id-type="publisher-id">JORM</journal-id>
<journal-title-group>
<journal-title>Journal of Oral &amp; Maxillofacial Research</journal-title>
</journal-title-group>
<issn pub-type="epub">2029-283X</issn>
<publisher>
<publisher-name>Stilus Optimus</publisher-name>
<publisher-loc>Kaunas, Lithuania</publisher-loc>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="publisher-id">v9n1e3ht</article-id>
<article-id pub-id-type="doi">10.5037/jomr.2018.9103</article-id>

<article-categories>
<subj-group subj-group-type="heading">
<subject>Original Paper</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Immunohistochemical Study of Laminin-332 γ2 Chain and MMP-9 in High Risk of Malignant Transformation Oral Lesions and OSCC</article-title>
</title-group>

<contrib-group>
<contrib contrib-type="author" id="contrib1">
<name>
<surname>Silva</surname>
<given-names>Eline Manhães Reid</given-names>
</name>
<xref ref-type="aff" rid="aff1">1</xref>
</contrib>
<contrib contrib-type="author" id="contrib2">
<name>
<surname>Freitas</surname>
<given-names>Vanessa Morais</given-names>
</name>
<xref ref-type="aff" rid="aff2">2</xref>
</contrib>
<contrib contrib-type="author" id="contrib3">
<name>
<surname>Bautz</surname>
<given-names>Willian Grassi</given-names>
</name>
<xref ref-type="aff" rid="aff3">3</xref>
</contrib>
<contrib contrib-type="author" id="contrib4">
<name>
<surname>de Barros</surname>
<given-names>Liliana Aparecida Pimenta</given-names>
</name>
<xref ref-type="aff" rid="aff1">1</xref>
</contrib>
<contrib contrib-type="author" id="contrib5" corresp="yes">
<name>
<surname>Gama de Souza</surname>
<given-names>Letícia Nogueira da</given-names>
</name>
<xref ref-type="aff" rid="aff3">3</xref>
</contrib>
</contrib-group>

<aff id="aff1" rid="aff1">
<sup>1</sup>
<institution>Dental Clinic, Federal University of Espírito Santo, Health of Sciences Center</institution><country>Brazil.</country>
</aff>
<aff id="aff2" rid="aff2">
<sup>2</sup>
<institution>Department of Cell and Developmental Biology, Institute of Biomedical Sciences, University of São Paulo</institution><country>Brazil.</country>
</aff>
<aff id="aff3" rid="aff3">
<sup>3</sup>
<institution>Department of Morphology, Health of Sciences Center, Federal University of Espírito Santo</institution><country>Brazil.</country>
</aff>

<author-notes>
<corresp>Letícia Nogueira da Gama de Souza, 
<institution>Department of Morphology, Health of Sciences Center</institution>
<institution>Federal University of Espírito Santo</institution>
<addr-line>Marechal Campos av., 1468, Maruípe, 29.040-090, Vitória, ES</addr-line>
<country>Brazil</country>
<phone>+552733357358</phone>
<email>leticia.souza@ufes.br</email>
</corresp>
</author-notes>

<pub-date pub-type="collection">
<season>Jan-Mar</season>
<year>2018</year>
</pub-date>
<pub-date pub-type="epub">
<day>31</day>
<month>3</month>
<year>2018</year>
</pub-date>
<volume>9</volume>
<issue>1</issue>
<elocation-id>e3</elocation-id>
<history>
<date date-type="received">
<day>21</day>
<month>9</month>
<year>2017</year>
</date>
<date date-type="accepted">
<day>10</day>
<month>3</month>
<year>2018</year>
</date>
</history>
<permissions>

<copyright-statement>Copyright &#169; Silva EMR, Freitas VM, Bautz WG, de Barros LAP, Gama de Souza LN. Published in the JOURNAL OF ORAL &amp; MAXILLOFACIAL RESEARCH (http://www.ejomr.org), 31 March 2018.
</copyright-statement>
<copyright-year>2018</copyright-year>
<license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by-nc-nd/3.0/">
<license-p>
This is an open-access article, first published in the JOURNAL OF ORAL &amp; MAXILLOFACIAL RESEARCH, distributed under the terms of the Creative Commons Attribution-Noncommercial-No Derivative Works 3.0 UnportedLicense (http://creativecommons.org/licenses/by-nc-nd/3.0/), which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work and is properly cited. The copyright, license information and link to the original publication on (http://www.ejomr.org) must be included.</license-p>
</license>
</permissions>

<self-uri xlink:href="http://www.ejomr.org/JOMR/archives/2018/1/e3/v9n1e3ht.htm" xlink:type="simple"/>


<abstract>
<title>ABSTRACT</title>
<sec sec-type="objectives">
<title>Objectives</title>
<p>Oral squamous cell carcinoma is associated with alterations in basement membrane. Laminin-332 is present in basal lamina and performs multiple biologic effects by γ2 chain. Matrix metalloproteinase acts disrupting extracellular components and was related to poor prognosis in cancer. Here, molecular profile of laminin-332 γ2 chain and matrix metalloproteinase-9 was assessed in oral lesions.</p>
</sec>
<sec sec-type="material and methods">
<title>Material and Methods</title>
<p>The expression of laminin-332 γ2 chain and matrix metalloproteinase-9 (MMP-9) was examined by immunohistochemistry in 10 patients with high risk of malignant transformation oral lesions and 26 cases of oral squamous cell carcinoma (OSCC). Associations between microscopic and clinicopathologic features were established.</p>
</sec>
<sec sec-type="results">
<title>Results</title>
<p>Immunostaining of laminin-332 γ2 chain in high risk oral lesions was most detected in basement membrane which is continuous, while the majority of OSCC cases showed a discontinuous membrane (P = 0.001). It was observed a positive reaction for γ2 chain in invasive fronts and a higher expression in epithelial compartment of smoking patients with OSCC (P &lt; 0.0001). In epithelium, MMP-9 expression was presented in all layers with no difference between lesions. However, an elevated immunostaining in stromal cells was associated with male patients (P = 0.0054), older than 60 years (P = 0.0101) and with OSCC.</p>
</sec>
<sec sec-type="conclusions">
<title>Conclusions</title>
<p>Present study results support the hypothesis of changes in molecules expression in high risk oral lesions and oral squamous cell carcinoma. A relation between clinical and molecule profile was observed. Those molecules may represent a useful tool to predict oral cancer behaviour.</p>
</sec>
</abstract>

<kwd-group>
<kwd>carcinogenesis</kwd>
<kwd>laminin</kwd>
<kwd>matrix metalloproteinase 9</kwd>
<kwd>oral cancer</kwd>
<kwd>oral pathology</kwd>
<kwd>squamous cell carcinoma</kwd>
</kwd-group>
</article-meta>
</front>

<body>
<sec sec-type="intro">
<title>INTRODUCTION</title>
<p>Oral squamous cell carcinoma (OSCC) is the most common oral cancer with 90% of the cases [<xref ref-type="bibr" rid="B1">1</xref>]. Tobacco is the main risk factor, and OSCC is linked to excessive consumption of alcohol and HPV infection [<xref ref-type="bibr" rid="B2">2</xref>]. OSCC may arise from oral potentially malignant disorders (OPMDs). Clinically, oral leukoplakia is one of the most common type of OPMD, with a malignant transformation rate between 2 - 3% per year [<xref ref-type="bibr" rid="B3">3</xref>,<xref ref-type="bibr" rid="B4">4</xref>]. Histopathologically, oral epithelial dysplasia (OED) is the most important feature of OPMDs and was considered as the progenitor for malignant changes [<xref ref-type="bibr" rid="B5">5</xref>].</p>
<p>Regarding cancer progression, one important step is the alteration that affects basement membrane, a dynamic structure composed of type IV collagen, proteoglycans and a dense network of glycoproteins [<xref ref-type="bibr" rid="B6">6</xref>]. Laminin-332 is a large extracellular glycoprotein presents in basal lamina of epithelial cells. This molecule performs multiple biologic effects, such as cell attachment, migration, differentiation and proliferation [<xref ref-type="bibr" rid="B7">7</xref>]. Recent studies have shown that biological activity of laminin-332 is modulated by γ2 chain process [<xref ref-type="bibr" rid="B8">8</xref>,<xref ref-type="bibr" rid="B9">9</xref>]. Matrix metalloproteinase (MMP) acts disrupting extracellular components which result in changes of cell-cell and cell-matrix interactions [<xref ref-type="bibr" rid="B10">10</xref>]. Among the various types of MMPs, MMP-9 has been highlighted in the context of tumorigenesis. Those enzymes were considered the new biomarkers for cancer in many sites, such as breast (MMP-1, -9, -13), lungs (MMP-1, -7, -9) and colorectal area (MMP-1, -2, -7, -9, -13) [<xref ref-type="bibr" rid="B11">11-13</xref>].</p>
<p>Clinic and morphologic parameters of OSCC are well defined by literature and histologic grading has been applied to define oral cancer behaviour for years, however, is important to emphasize that its prognostic value is still considered controversial. Thus, our objective was to assess the laminin-332 γ2 chain and matrix metalloproteinase-9 expression in high risk of malignant transformation oral lesions and oral squamous cell carcinoma. Also, the microscopic features were associated to patient’s clinical data and its possible implication in carcinogenesis.</p>
</sec>

<sec sec-type="materials|methods">
<title>MATERIAL AND METHODS</title>
<p><bold>Patients and tissue specimens</bold></p>
<p>The retrospective study was approved by Ethics Committee of the Institution where it was developed (protocols 45995815.9.0000.5060 - Federal University of Espírito Santo/UFES, Brazil) and was performed in accordance with the Declaration of Helsinki. Paraffin embedded tissues from different sites were selected from the archives of the Oral Pathology Laboratory of Dentistry School/UFES between 2004 and 2011. A total of 36 lesions were selected and the confirmation of initial diagnosis were performed by oral pathologist (L.A.P.B.). The architectural and cytological scoring criteria for OED were applied in OPMD to define groups. The group of high risk oral lesions was consisted by 5 cases diagnosed microscopically with severe OED in accordance with the binary system proposed by Kujan et al. [<xref ref-type="bibr" rid="B5">5</xref>] for potential susceptibility for malignant transformation and 5 cases of CIS. The OSCC group consisted by 26 invasive OSCCs (9 well differentiated, 11 moderately differentiated and 6 undifferentiated). Cases of inflammatory fibrous hyperplasia (IFH) was included as a positive/negative control of the pattern expression of the studied molecules. Clinical data were collected from medical records and included: gender, age, lesion site and history of tobacco exposure. Exclusion criteria were: incomplete clinical data and insufficient sample for microscopic analysis.</p>
<p><bold>Immunohistochemistry</bold></p>
<p>For immunohistochemistry, 3 µm sections were submitted to the immunoperoxidase method. The primary antibodies used were: mouse anti-γ2 chain laminin-332 with dilution 1:100 (clone B-2: sc-25341, Santa Cruz Biotechnology, Santa Cruz, CA) and rabbit anti-MMP-9 with dilution 1:500 (whole molecule-ab 38898, Abcam). Immunodetection was performed with the Reveal System (Spring/Biogen SPB-999) using 3,3′-diaminobenzidine as the chromogen. The sections were counterstained with Mayer’s haematoxylin. Heat citrate buffer pH 6.0 was used for antigen retrieval and 1% bovine serum albumin (BSA) was applied for blocking non-specific antigens. The sections were incubated with the respective primary antibodies overnight in a humidified chamber maintained at 4 °C. Then, slides were depleted of endogenous peroxidase by incubating for 20 min with 3% hydrogen peroxide in room temperature. Subsequently, specimens were incubated with secondary antibody detection system according manufacturer’s instructions. Positive (IFH) and negative controls (omission of primary antibody) were included.</p>
<p><bold>Microscopic analysis</bold></p>
<p>Immunostained sections were analysed and scored in a blind manner with respect to clinical information by a single investigator, previously calibrated (kappa 0.8) using Olympus AX70 microscope (Olympus America Inc., NY, USA) with a digital camera Zeiss AxioCam ERC5s (Carl Zeiss Vision GmbH, Germany) coupled and Axio Vision 4.2 Release 4.8.2 images program (Carl Zeiss Vision GmbH, Germany). The expression of laminin-332 γ2 chain was evaluated according to tissue sites: (1) basement membrane and (2) epithelial compartment. For the last one, cells were separated into a basal layer (BL) and a suprabasal layer (SL). The BL consisted of one to two cell layers that were closest and perpendicularly organized on the epithelial-matrix interface. The rest of the epithelial cells overlying BL were designated as SL [<xref ref-type="bibr" rid="B7">7</xref>]. Expression was still analysed in invasive front and tumour nests. Regarding basement membrane staining, the following aspects were considered: absence; continuity; discontinuity. All slides were evaluated at x100 magnification. In relation to MMP-9 analysis, stroma and epithelium (BL+SL) were also considered. The number of stromal cells expressing MMP-9 was divided by total fields (cells/fields: C/F ratio). After that, 3 groups were established: fewer than 25% of the labelled cells, 25 - 50% labelled and more than 50% of stained cells [<xref ref-type="bibr" rid="B14">14</xref>].</p>
<p><bold>Association of clinical and microscopic data</bold></p>
<p>After microscopic analysis and data collection, associations between molecules expression and clinical parameters were established. Each of those clinical data (age, gender, site and tobacco exposure) were examined and correlated with molecules expression according to criteria described above.</p>

<p><bold>Statistical analysis</bold></p>
<p>Chi-squared test was applied to evaluate clinical data. Chi-square Test, Fischer`s Exact Test and Two-way ANOVA were used to analyse correlations between molecules expression and clinical data. The results were considered significant when P &lt; 0.05. GraphPad Prism 5 (GraphPad Software, San Diego, CA, USA) was used for statistical analysis.</p>
</sec>

<sec sec-type="results">
<title>RESULTS</title>
<p><bold>Clinical data</bold></p>
<p>Male was the most affected gender i.e. 70% in high risk oral lesions and 88.5% in OSCC cases. Patients older than 60 years were more prevalent in high risk oral lesions (80%). In OSCC most patients were under 60 years (57.7%). Lesions affected different sites and was predominantly in the alveolar ridge. Most of patients related smoking, especially in OSCC (77%). <xref ref-type="table" rid="T1">Table 1</xref> summarized clinical data.</p>
<p><bold>Expression of laminin-332 γ2 chain and MMP-9</bold></p>

<table-wrap id="T1" position="float">
<label>Table 1</label>
<caption>
<p>
Clinical data and histologic status of studied groups
</p>
</caption>
<table frame="hsides" rules="groups">
<thead>
<tr>
<th>
</th>
<th>
Case
</th>
<th>
Histologic status
</th>
<th>
Gender
</th>
<th>
Site
</th>
<th>
Age<break />
(years)
</th>
<th>
Habit
</th>
</tr>
</thead>
<tbody>
<tr>
<td  rowspan="19" align="left">
<bold>High risk</bold><break />
<bold>oral lesion
		  </bold></td>
<td align="center">
1
</td>
<td align="center">
Severe OED
</td>
<td align="center">
M
</td>
<td align="center">
Alveolar ridge
</td>
<td align="center">
67
</td>
<td align="center">
S
</td>
</tr>
<tr>
<td colspan="6" align="center"><hr/></td>
</tr>
<tr>
<td align="center">
2
</td>
<td align="center">
Severe OED
</td>
<td align="center">
F
</td>
<td align="center">
Lip
</td>
<td align="center">
61
</td>
<td align="center">
NS
</td>
</tr>
<tr>
<td colspan="6" align="center"><hr/></td>
</tr>
<tr>
<td align="center">
3
</td>
<td align="center">
Severe OED
</td>
<td align="center">
F
</td>
<td align="center">
Alveolar ridge
</td>
<td align="center">
66
</td>
<td align="center">
S
</td>
</tr>
<tr>
<td colspan="6" align="center"><hr/></td>
</tr>
<tr>
<td align="center">
4
</td>
<td align="center">
Severe OED
</td>
<td align="center">
M
</td>
<td align="center">
Alveolar ridge
</td>
<td align="center">
77
</td>
<td align="center">
S
</td>
</tr>
<tr>
<td colspan="6" align="center"><hr/></td>
</tr>
<tr>
<td align="center">
5
</td>
<td align="center">
Severe OED
</td>
<td align="center">
F
</td>
<td align="center">
Tongue
</td>
<td align="center">
47
</td>
<td align="center">
NS
</td>
</tr>
<tr>
<td colspan="6" align="center"><hr/></td>
</tr>
<tr>
<td align="center">
6
</td>
<td align="center">
CIS
</td>
<td align="center">
M
</td>
<td align="center">
Alveolar ridge
</td>
<td align="center">
61
</td>
<td align="center">
S
</td>
</tr>
<tr>
<td colspan="6" align="center"><hr/></td>
</tr>
<tr>
<td align="center">
7
</td>
<td align="center">
CIS
</td>
<td align="center">
M
</td>
<td align="center">
Alveolar ridge
</td>
<td align="center">
30
</td>
<td align="center">
NS
</td>
</tr>
<tr>
<td colspan="6" align="center"><hr/></td>
</tr>
<tr>
<td align="center">
8
</td>
<td align="center">
CIS
</td>
<td align="center">
M
</td>
<td align="center">
Tongue
</td>
<td align="center">
61
</td>
<td align="center">
S
</td>
</tr>
<tr>
<td colspan="6" align="center"><hr/></td>
</tr>
<tr>
<td align="center">
9
</td>
<td align="center">
CIS
</td>
<td align="center">
M
</td>
<td align="center">
Alveolar ridge
</td>
<td align="center">
64
</td>
<td align="center">
S
</td>
</tr>
<tr>
<td colspan="6" align="center"><hr/></td>
</tr>
<tr>
<td align="center">
10
</td>
<td align="center">
CIS
</td>
<td align="center">
M
</td>
<td align="center">
Alveolar ridge
</td>
<td align="center">
68
</td>
<td align="center">
NS
</td>
</tr>
<tr>
<td colspan="7"><hr/></td>
</tr>
<tr>
<td  rowspan="51" align="left">
<bold>Oral squamous</bold><break />
<bold>cell carcinoma
		  </bold></td>
<td align="center">
11
</td>
<td align="center">
Well differentiated
</td>
<td align="center">
M
</td>
<td align="center">
Mouth floor
</td>
<td align="center">
79
</td>
<td align="center">
S
</td>
</tr>
<tr>
<td colspan="6" align="center"><hr/></td>
</tr>
<tr>
<td align="center">
12
</td>
<td align="center">
Well differentiated
</td>
<td align="center">
M
</td>
<td align="center">
Mouth floor
</td>
<td align="center">
45
</td>
<td align="center">
S
</td>
</tr>
<tr>
<td colspan="6" align="center"><hr/></td>
</tr>
<tr>
<td align="center">
13
</td>
<td align="center">
Well differentiated
</td>
<td align="center">
M
</td>
<td align="center">
Alveolar ridge
</td>
<td align="center">
52
</td>
<td align="center">
S
</td>
</tr>
<tr>
<td colspan="6" align="center"><hr/></td>
</tr>
<tr>
<td align="center">
14
</td>
<td align="center">
Well differentiated
</td>
<td align="center">
M
</td>
<td align="center">
Mouth floor
</td>
<td align="center">
53
</td>
<td align="center">
S
</td>
</tr>
<tr>
<td colspan="6" align="center"><hr/></td>
</tr>
<tr>
<td align="center">
15
</td>
<td align="center">
Well differentiated
</td>
<td align="center">
F
</td>
<td align="center">
Alveolar ridge
</td>
<td align="center">
46
</td>
<td align="center">
NS
</td>
</tr>
<tr>
<td colspan="6" align="center"><hr/></td>
</tr>
<tr>
<td align="center">
16
</td>
<td align="center">
Well differentiated
</td>
<td align="center">
M
</td>
<td align="center">
Mouth floor
</td>
<td align="center">
58
</td>
<td align="center">
S
</td>
</tr>
<tr>
<td colspan="6" align="center"><hr/></td>
</tr>
<tr>
<td align="center">
17
</td>
<td align="center">
Well differentiated
</td>
<td align="center">
M
</td>
<td align="center">
Alveolar ridge
</td>
<td align="center">
42
</td>
<td align="center">
S
</td>
</tr>
<tr>
<td colspan="6" align="center"><hr/></td>
</tr>
<tr>
<td align="center">
18
</td>
<td align="center">
Well differentiated
</td>
<td align="center">
M
</td>
<td align="center">
Lip
</td>
<td align="center">
70
</td>
<td align="center">
S
</td>
</tr>
<tr>
<td colspan="6" align="center"><hr/></td>
</tr>
<tr>
<td align="center">
19
</td>
<td align="center">
Well differentiated
</td>
<td align="center">
M
</td>
<td align="center">
Alveolar ridge
</td>
<td align="center">
66
</td>
<td align="center">
S
</td>
</tr>
<tr>
<td colspan="6" align="center"><hr/></td>
</tr>
<tr>
<td align="center">
20
</td>
<td align="center">
Moderately differentiated
</td>
<td align="center">
M
</td>
<td align="center">
Tongue
</td>
<td align="center">
49
</td>
<td align="center">
NS
</td>
</tr>
<tr>
<td colspan="6" align="center"><hr/></td>
</tr>
<tr>
<td align="center">
21
</td>
<td align="center">
Moderately differentiated
</td>
<td align="center">
M
</td>
<td align="center">
Mouth floor
</td>
<td align="center">
53
</td>
<td align="center">
S
</td>
</tr>
<tr>
<td colspan="6" align="center"><hr/></td>
</tr>
<tr>
<td align="center">
22
</td>
<td align="center">
Moderately differentiated
</td>
<td align="center">
M
</td>
<td align="center">
Tongue
</td>
<td align="center">
51
</td>
<td align="center">
S
</td>
</tr>
<tr>
<td colspan="6" align="center"><hr/></td>
</tr>
<tr>
<td align="center">
23
</td>
<td align="center">
Moderately differentiated
</td>
<td align="center">
M
</td>
<td align="center">
Mouth floor
</td>
<td align="center">
79
</td>
<td align="center">
S
</td>
</tr>
<tr>
<td colspan="6" align="center"><hr/></td>
</tr>
<tr>
<td align="center">
24
</td>
<td align="center">
Moderately differentiated
</td>
<td align="center">
F
</td>
<td align="center">
Alveolar ridge
</td>
<td align="center">
85
</td>
<td align="center">
S
</td>
</tr>
<tr>
<td colspan="6" align="center"><hr/></td>
</tr>
<tr>
<td align="center">
25
</td>
<td align="center">
Moderately differentiated
</td>
<td align="center">
M
</td>
<td align="center">
Tongue
</td>
<td align="center">
64
</td>
<td align="center">
S
</td>
</tr>
<tr>
<td colspan="6" align="center"><hr/></td>
</tr>
<tr>
<td align="center">
26
</td>
<td align="center">
Moderately differentiated
</td>
<td align="center">
M
</td>
<td align="center">
Tongue
</td>
<td align="center">
74
</td>
<td align="center">
S
</td>
</tr>
<tr>
<td colspan="6" align="center"><hr/></td>
</tr>
<tr>
<td align="center">
27
</td>
<td align="center">
Moderately differentiated
</td>
<td align="center">
M
</td>
<td align="center">
Mouth floor
</td>
<td align="center">
51
</td>
<td align="center">
S
</td>
</tr>
<tr>
<td colspan="6" align="center"><hr/></td>
</tr>
<tr>
<td align="center">
28
</td>
<td align="center">
Moderately differentiated
</td>
<td align="center">
M
</td>
<td align="center">
Buccal mucosa
</td>
<td align="center">
74
</td>
<td align="center">
NS
</td>
</tr>
<tr>
<td colspan="6" align="center"><hr/></td>
</tr>
<tr>
<td align="center">
29
</td>
<td align="center">
Moderately differentiated
</td>
<td align="center">
F
</td>
<td align="center">
Alveolar Ridge
</td>
<td align="center">
89
</td>
<td align="center">
NS
</td>
</tr>
<tr>
<td colspan="6" align="center"><hr/></td>
</tr>
<tr>
<td align="center">
30
</td>
<td align="center">
Moderately differentiated
</td>
<td align="center">
M
</td>
<td align="center">
Alveolar ridge
</td>
<td align="center">
51
</td>
<td align="center">
S
</td>
</tr>
<tr>
<td colspan="6" align="center"><hr/></td>
</tr>
<tr>
<td align="center">
31
</td>
<td align="center">
Undifferentiated
</td>
<td align="center">
M
</td>
<td align="center">
Buccal mucosa
</td>
<td align="center">
50
</td>
<td align="center">
NS
</td>
</tr>
<tr>
<td colspan="6" align="center"><hr/></td>
</tr>
<tr>
<td align="center">
32
</td>
<td align="center">
Undifferentiated
</td>
<td align="center">
M
</td>
<td align="center">
Alveolar ridge
</td>
<td align="center">
67
</td>
<td align="center">
S
</td>
</tr>
<tr>
<td colspan="6" align="center"><hr/></td>
</tr>
<tr>
<td align="center">
33
</td>
<td align="center">
Undifferentiated
</td>
<td align="center">
M
</td>
<td align="center">
Alveolar ridge
</td>
<td align="center">
38
</td>
<td align="center">
S
</td>
</tr>
<tr>
<td colspan="6" align="center"><hr/></td>
</tr>
<tr>
<td align="center">
34
</td>
<td align="center">
Undifferentiated
</td>
<td align="center">
M
</td>
<td align="center">
Mouth floor
</td>
<td align="center">
49
</td>
<td align="center">
S
</td>
</tr>
<tr>
<td colspan="6" align="center"><hr/></td>
</tr>
<tr>
<td align="center">
35
</td>
<td align="center">
Undifferentiated
</td>
<td align="center">
M
</td>
<td align="center">
Alveolar ridge
</td>
<td align="center">
68
</td>
<td align="center">
NS
</td>
</tr>
<tr>
<td colspan="6" align="center"><hr/></td>
</tr>
<tr>
<td align="center">
36
</td>
<td align="center">
Undifferentiated
</td>
<td align="center">
M
</td>
<td align="center">
Tongue
</td>
<td align="center">
46
</td>
<td align="center">
S
</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn>
<p>
OED = oral epithelial dysplasia; CIS = carcinoma <italic>in situ</italic>; M = male; F = female; S = smoking; NS = non-smoking.
</p>
</fn>
</table-wrap-foot>
</table-wrap>

<p>Immunostaining of laminin-332 γ2 chain in basement membrane demonstrated differences. In high risk oral lesions, all cases showed staining in basement membrane and 60% were presented as a continuous profile (<xref ref-type="fig" rid="fig1">Figure 1C</xref>). In OSCC, 69.2% of cases had a discontinuous or no visible membrane (<xref ref-type="fig" rid="fig1">Figure 1E</xref>, <xref ref-type="fig" rid="fig1">G</xref>). That difference was statistically significant (P = 0.001). Related to positive expression in epithelial cells, a preferential staining in BL+SL (<xref ref-type="fig" rid="fig1">Figure 1E</xref>, <xref ref-type="fig" rid="fig1">F</xref>) was observed with no statistical difference between lesions (<xref ref-type="table" rid="T2">Table 2</xref>). Laminin-332 expression was detected in OSCC predominantly in single cells, periphery tumour nests or tumour-stromal interface of invasive fronts (<xref ref-type="fig" rid="fig1">Figure 1G</xref>). All cases of OSCC with invasive fronts showed positive expression for laminin-332 γ2 chain in epithelial cells and a cellular membrane staining was remarkable (<xref ref-type="fig" rid="fig1">Figure 1G</xref>, arrowheads). When MMP-9 was analysed in epithelium, it was possible to observe the expression in all layers (<xref ref-type="fig" rid="fig1">Figure 1D</xref>, <xref ref-type="fig" rid="fig1">F</xref>) with no significant difference between lesions (<xref ref-type="table" rid="T2">Table 2</xref>). However, the analysis of stromal cells showed a higher (P = 0.0086) MMP-9 expression (50% cells/field) in OSCC (<xref ref-type="fig" rid="fig1">Figure 1H</xref>, <xref ref-type="table" rid="T2">Table 2</xref>). The positive control of laminin-332 was observed as a discrete and continuous linear basement membrane in IFH (<xref ref-type="fig" rid="fig1">Figure 1A</xref>, arrow). Positive expression of MMP-9 was mainly observed in endothelial cell of small vessels (<xref ref-type="fig" rid="fig1">Figure 1B</xref>, * symbol). Neither antibodies showed staining brownish granules in BL and SL.</p>

<fig id="fig1">
<label>Figure 1</label>
<caption>
<p>
Expression of laminin-332 γ2 chain and MMP-9 in high risk of malignant transformation oral lesions and oral squamous cell carcinoma (OSCC) was examined by immunohistochemistry. Scale bar = 20 μm.</p>
<p>A = Positive control of laminin-332 γ2 chain along epithelial-stromal interface, showing a linear structure (arrow).</p>
<p>B = MMP-9 expression in endothelial cells of IFH (* symbol).</p>
<p>C = High risk oral lesion with continuous basement membrane (arrow).</p>
<p>D = MMP-9 citoplasmatic staining in epithelium cells.</p>
<p>E = OSCC well differentiated with areas of continuous basement membrane (arrows) and laminin-332 γ2 chain expression in SL.</p>
<p>F = Epithelium citoplasmatic expression of MMP-9 in OSCC.</p>
<p>G = Areas of invasive front with laminin-332 γ2 chain citoplasmatic expression and a cellular membrane staining in OSCC moderately differentiated (arrowhead).</p>
<p>H = Enzyme expression in stromal cells surrounding OSCC nests.</p>
<p>IFH = inflammatory fibrous hyperplasia; MMP = matrix metalloproteinase; BL = basal layer; SL = suprabasal layer.</p>
</caption>
<graphic xlink:href="jomr-09-e3-g001.jpg"/>
</fig>

<table-wrap id="T2" position="float">
<label>Table 2</label>
<caption>
<p>
Expression of laminin-332 γ2 chain and MMP- 9
</p>
</caption>
<table frame="hsides" rules="groups">
<thead>
<tr>
<th>
Expression
</th>
<th>
High risk oral lesion<break />
(n = 10)
</th>
<th>
OSCC<break />
(n = 26)
</th>
<th>
P-value
</th>
</tr>
</thead>
<tbody>
<tr>
<td  colspan="4" align="left">
<bold>Laminin-332 γ2 in basement membrane </bold></td>
</tr>
<tr>
<td colspan="4"><hr/></td>
</tr>
<tr>
<td align="center">
Continuous
</td>
<td align="center">
60% (n = 6)
</td>
<td align="center">
0
</td>
<td  rowspan="5" align="center">
0.000<sup>a</sup>
</td>
</tr>
<tr>
<td colspan="3" align="center"><hr/></td>
</tr>
<tr>
<td align="center">
Discontinuous
</td>
<td align="center">
40% (n = 4)
</td>
<td align="center">
69.2% (n = 18)
</td>
</tr>
<tr>
<td colspan="3" align="center"><hr/></td>
</tr>
<tr>
<td align="center">
Absence
</td>
<td align="center">
0
</td>
<td align="center">
30.8% (n = 8)
</td>
</tr>
<tr>
<td colspan="4"><hr/></td>
</tr>
<tr>
<td  colspan="3" align="left">
<bold>Laminin-332 γ2 in epithelium </bold></td>
<td align="left">
</td>
</tr>
<tr>
<td colspan="4"><hr/></td>
</tr>
<tr>
<td align="center">
BL
</td>
<td align="center">
10% (n = 1)
</td>
<td align="center">
35% (n = 7)
</td>
<td  rowspan="3" align="center">
0.2103
</td>
</tr>
<tr>
<td colspan="3" align="center"><hr/></td>
</tr>
<tr>
<td align="center">
BL+SL
</td>
<td align="center">
90% (n=9)
</td>
<td align="center">
65% (n = 13)
</td>
</tr>
<tr>
<td colspan="4"><hr/></td>
</tr>
<tr>
<td  colspan="4" align="left">
<bold>MMP-9 in epithelium </bold></td>
</tr>
<tr>
<td colspan="4"><hr/></td>
</tr>
<tr>
<td align="center">
BL
</td>
<td align="center">
50% (n = 5)
</td>
<td align="center">
35% (n = 7)
</td>
<td  rowspan="5" align="center">
0.4072
</td>
</tr>
<tr>
<td colspan="3" align="center"><hr/></td>
</tr>
<tr>
<td align="center">
SL
</td>
<td align="center">
30% (n = 3)
</td>
<td align="center">
20% (n = 4)
</td>
</tr>
<tr>
<td colspan="3" align="center"><hr/></td>
</tr>
<tr>
<td align="center">
BL+SL
</td>
<td align="center">
20% (n = 2)
</td>
<td align="center">
45% (n = 9)
</td>
</tr>
<tr>
<td colspan="4"><hr/></td>
</tr>
<tr>
<td  colspan="4" align="left">
<bold>MMP-9 stroma/field </bold></td>
</tr>
<tr>
<td colspan="4"><hr/></td>
</tr>
<tr>
<td align="center">
&lt; 25% cells/field
</td>
<td align="center">
40% (n = 4)
</td>
<td align="center">
11,5% (n = 3)
</td>
<td  rowspan="5" align="center">
0.0086<sup>a</sup>
</td>
</tr>
<tr>
<td colspan="3" align="center"><hr/></td>
</tr>
<tr>
<td align="center">
25 - 50% cells/field
</td>
<td align="center">
50% (n = 5)
</td>
<td align="center">
15,4% (n = 4)
</td>
</tr>
<tr>
<td colspan="3" align="center"><hr/></td>
</tr>
<tr>
<td align="center">
&gt; 50% cells/field
</td>
<td align="center">
10% (n = 1)
</td>
<td align="center">
73.1% (n = 19)
</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn>
<p>
<sup>a</sup>Chi-square test (significance level P &lt; 0.05).
</p>
<p>
OSCC = oral squamous cell carcinoma; MMP = matrix metalloproteinase; BL = basal layer; SL = suprabasal layer.
</p>
</fn>
</table-wrap-foot>
</table-wrap>

<p><bold>Association between clinical data and expression of laminin-332 γ2 chain and MMP-9</bold></p>
<p>Associations between data showed positive results. When only smokers were analysed, those with OSCC had a higher expression of laminin-332 γ2 chain in BL and BL+SL when compared to high risk oral cases (P &lt; 0.0001) risk oral cases (<xref ref-type="fig" rid="fig2">Figure 2A</xref>). The same was not observed in basement membrane. The analysis showed no difference of laminin expression between lesions of smokers (<xref ref-type="fig" rid="fig2">Figure 2B</xref>). Regarding MMP-9 expression, when only male patients were analysed, those with OSCC showed more stromal cells with citoplasmatic staining than high risk oral cases (P = 0.0054) (<xref ref-type="fig" rid="fig2">Figure 2C</xref>). The same pattern was observed in patients older than 60 years, with a higher number of stromal cells with MMP-9 expression in OSCC cases than high risk oral lesions (P = 0.0101) (<xref ref-type="fig" rid="fig2">Figure 2D</xref>). The analysis of MMP-9 in invasive fronts demonstrated that smokers had a higher (P = 0.0225) expression when compared with non-smokers (<xref ref-type="fig" rid="fig2">Figure 2E</xref>). Finally, when the group of patients with laminin-332 expression in BL+SL was evaluated, OSCC cases showed a higher frequency of stromal cells with citoplasmatic staining of MMP-9 than high risk oral lesions (P = 0.003) risk oral lesions (<xref ref-type="fig" rid="fig2">Figure 2F</xref>).</p>

<fig id="fig2">
<label>Figure 2</label>
<caption>
<p>
Graph analysis of association between clinical data and molecules expression.</p>
<p>A = Smokers with OSCC had a higher expression of laminin-332 γ2 chain in BL and BL+SL than high risk oral cases (P &lt; 0.0001).</p>
<p>B = The same was not observed in basement membrane (P &gt; 0.05).</p>
<p>C = Regarding MMP-9 expression, male patients with OSCC showed more stromal cells with citoplasmatic staining than high risk oral cases (P = 0.0054).</p>
<p>D = The same pattern was observed in patients older than 60 years (P = 0.0101).</p>
<p>E = The analysis of MMP-9 in invasive fronts demonstrated that smokers had a higher expression when compared with non-smokers (P = 0.0225).</p>
<p>F = Group of patients with laminin-332 expression in BL+SL with OSCC showed a higher frequency of stromal cells with citoplasmatic staining of MMP-9 than high risk oral lesions (P = 0.003).</p>
<p><sup>a</sup>Two-way ANOVA (A and B), <sup>b</sup>Chi-square test (C, D and F) and <sup>c</sup>Fischer`s Exact test (E) (significance level P &lt; 0.05).</p>
<p>OSCC = oral squamous cell carcinoma; MMP = matrix metalloproteinase; BL = basal layer; SL = suprabasal layer.</p>
</caption>
<graphic xlink:href="jomr-09-e3-g002.jpg"/>
</fig>
</sec>

<sec sec-type="discussion">
<title>DISCUSSION</title>
<p>The study sought to analyse molecular profile of laminin-332 γ2 chain and MMP-9 in high risk oral lesions and OSCC. In addition, microscopic features were evaluated in order to detected possible associations between histological and clinical factors. Our data demonstrated a discontinuous basement membrane and a higher expression of laminin-332 γ2 chain in epithelial compartment and invasive fronts related to smoking patients diagnosed with OSCC. Moreover, MMP-9 expression in stromal cells was prevalent in male.</p>
<p>Regarding clinical data, in high risk oral lesions individuals over 60 years were more prevalent and in OSCC cases the main age was over 50 years. In a retrospective study of 295 cases of OSCC, 81% of patients were men, with 51 - 60 years and the most prevalent site was the mandibular alveolar ridge [<xref ref-type="bibr" rid="B15">15</xref>]. The authors mentioned that cigarette consumption was the main habit that led to oral cancer. Within the context of high risk oral lesions, usually occurred in middle age men and prevalence increased considerably over 70 years [<xref ref-type="bibr" rid="B16">16</xref>].</p>
<p>A relevant point to improve cancer diagnostics is the development of biomarkers to detected cell early alterations. In this context, histopathological changes in basement membrane is a well-recognized step in epithelial cancer progression [<xref ref-type="bibr" rid="B7">7</xref>]. This process has been shown to be critical in carcinogenesis once tumour cells need a substrate to invade and proliferate [<xref ref-type="bibr" rid="B17">17</xref>]. We analysed laminin-332 γ2 chain expression in tissues of high risk oral lesions and OSCC. Study results demonstrated that most of high risk oral cases had a continuous basement membrane and any lesion was detected with a completely absent membrane. On the other hand, in OSCC lesions major of cases had a discontinuous or absence membrane. Those findings are in agreement with Imura et al. [<xref ref-type="bibr" rid="B18">18</xref>] that demonstrated a continuous and linear basement membrane while disease has not reached advanced stages.</p>
<p>In the connective tissue, OSCC showed γ2 expression in the periphery of tumour islands and in the tumour-stroma interface, especially in areas of invasive fronts. Zargaran et al. [<xref ref-type="bibr" rid="B19">19</xref>] demonstrated that γ2 chain expression was preferably detected in cells of invasive fronts and it was associated with tumour progression. These findings suggest that laminin-332 could play a role in the acquisition of a migrating profile, a feature that is required for malignancy.</p>
<p>When only smoking patients were considered, the association of clinical data and laminin-332 γ2 chain expression demonstrated a higher staining in epithelium of OSCC cases when compared with high risk oral lesions. Tobacco is a well-known risk factor in carcinogenesis and it was related to the acquisition of mobility in tumour cells [<xref ref-type="bibr" rid="B20">20</xref>]. The literature associated proliferation, migration and invasion activities with a profoundly change in γ2 chain. Garg et al. [<xref ref-type="bibr" rid="B21">21</xref>] showed a decrease in migration and invasion when cells were treated with silencing LAMγ2. Additionally, laminin-332 stimulates tumour cells to form fine protrusions on the sheet-shaped front edge membranes, which led to an increase in cell migration and invasion to the underlying tissue [<xref ref-type="bibr" rid="B22">22</xref>]. So, it is possible to suggest a role of laminin-332 γ2 chain in getting a more aggressive cancer phenotype.</p>
<p>The loss of basement membrane may be associated with stromal invasion and metastatic process. MMPs are involved in cleavage process of basement membrane. MMP-9 synthesis by tumour cells is important to those processes and could represent a feature of disease aggressiveness [9]. Our analysis demonstrated a higher cytoplasmic staining of stromal cells (more than 50% cells/field) in OSCC patients when compared to high risk oral lesions. Tamamura et al. [<xref ref-type="bibr" rid="B14">14</xref>] described few or no expression of MMP-9 in OED, which is in agreement with our results. Regarding correlation between clinical data and MMP-9 expression, in the cases of smoker patients with OSCC an elevated expression was observed in invasive fronts. It is important to consider that MMPs have the ability to modulate tumour invasion and its expression is well recognized in areas such as tumour fronts [<xref ref-type="bibr" rid="B14">14</xref>].</p>
<p>When only male patients over 60 years were analysed, those diagnosed with OSCC showed more stromal cells with cytoplasmic labelling of MMP-9 than high risk oral lesions. The increase in diffuse brownish granules of MMP-9 represented a more aggressive behaviour of disease in males and elderly patients. According to Georgescu et al. [<xref ref-type="bibr" rid="B23">23</xref>], MMP-9 expression in the stromal cells of colorectal carcinoma was related to the propensity for invasion and metastasis. The study also demonstrated a higher expression of MMP-9 in peritumoral lymph nodes, although metastasis-free, suggesting that this enzyme is preparing tissue for a possible metastasis. Andisheh-Tadbir et al. [<xref ref-type="bibr" rid="B24">24</xref>] analysed 42 patients with OSCC and observed a statistical significance for tumour clinical stage. The authors found lymph nodes invasion in 100% of the samples with a high positive staining for MMP-9 in N1 stage. These data indicates aggressiveness of the OSCC related to MMP-9 expression.</p>
<p>Analysis of laminin-332 γ2 chain and MMP-9 expression in high risk oral lesions and OSCC may improve the understanding of different stages in oral carcinogenesis. Furthermore, seeking possible associations between molecules profile and clinical data may provide insight into how risk factors could modify tumour microenvironment.</p>
</sec>

<sec sec-type="conclusions">
<title>CONCLUSIONS</title>
<p>Our results support the hypothesis of changes in molecules expression in high risk oral lesions and oral squamous cell carcinoma. A relation between clinical and molecule profile was observed. A discontinuous basement membrane and a higher expression of laminin-332 γ2 chain in epithelial compartment and invasive fronts was related to smoking patients diagnosed with oral squamous cell carcinoma. Moreover, matrix metalloproteinase-9 expression in stromal cells was prevalent in male over 60 years. However, other aspects may also participate of those changes and should be the subject of further studies.</p>
</sec>
</body>

<back>
<ack>
<sec sec-type="acknowledgments and disclosure statements">
<title>ACKNOWLEDGMENTS AND DISCLOSURE STATEMENTS</title>
<p>This work was supported by grants from Brazilian National Council for Scientific and Technological Development (CNPq), process number: 479694 2013-3; and the State of Espírito Santo Research Foundation (FAPES), process number: 67659870 006/2014. E.M.R Callegari is a recipient of graduate fellowships from FAPES process number: 66882370/2014.</p>
<p>The authors declare no conflict of interest.</p>
</sec>
</ack>

<ref-list>
<title>REFERENCES</title>
  <ref id="B1"><label>1</label>
    <element-citation>
      <person-group person-group-type="author">
        <name>
<surname>Tabatabaeifar</surname>
<given-names>S</given-names>
</name><name>
<surname>Thomassen</surname>
<given-names>M</given-names>
</name><name>
<surname>Larsen</surname>
<given-names>MJ</given-names>
</name><name>
<surname>Larsen</surname>
<given-names>SR</given-names>
</name><name>
<surname>Kruse</surname>
<given-names>TA</given-names>
</name><name>
<surname>Sørensen</surname>
<given-names>JA</given-names>
</name>
</person-group>
<source>The subclonal structure and genomic evolution of oral squamous cell carcinoma revealed by ultra-deep sequencing. Oncotarget. 2017 Mar 7;8(10):16571-16580.</source>
<pub-id pub-id-type="pmid">28157713</pub-id>
<pub-id pub-id-type="pmcid">PMC 5369985</pub-id>
<pub-id pub-id-type="doi">10.18632/oncotarget.15014</pub-id>
</element-citation>
  </ref>
  <ref id="B2"><label>2</label>
    <element-citation>
      <person-group person-group-type="author">
        <name>
<surname>Bradley</surname>
<given-names>G</given-names>
</name><name>
<surname>Magalhaes</surname>
<given-names>MA</given-names>
</name><name>
<surname>Hyrcza</surname>
<given-names>M</given-names>
</name>
</person-group>
<source>Mutational signatures in oral cancer indicate a complex role for tobacco smoke carcinogens. Oral Dis. 2017 Mar 13.</source>
<pub-id pub-id-type="pmid">28295873</pub-id>
<pub-id pub-id-type="doi">10.1111/odi.12665</pub-id>
</element-citation>
  </ref>
  <ref id="B3"><label>3</label>
    <element-citation>
      <person-group person-group-type="author">
        <name>
<surname>van der Waal</surname>
<given-names>I</given-names>
</name>
</person-group>
<source>Oral potentially malignant disorders: is malignant transformation predictable and preventable? Med Oral Patol Oral Cir Bucal. 2014 Jul 1;19(4):e386-90.</source>
<pub-id pub-id-type="pmid">24905952</pub-id>
<pub-id pub-id-type="pmcid">PMC 4119315</pub-id>
<pub-id pub-id-type="doi">10.4317/medoral.20205</pub-id>
</element-citation>
  </ref>
  <ref id="B4"><label>4</label>
    <element-citation>
      <person-group person-group-type="author">
        <name>
<surname>Liu</surname>
<given-names>W</given-names>
</name><name>
<surname>Bao</surname>
<given-names>ZX</given-names>
</name><name>
<surname>Shi</surname>
<given-names>LJ</given-names>
</name><name>
<surname>Tang</surname>
<given-names>GY</given-names>
</name><name>
<surname>Zhou</surname>
<given-names>ZT</given-names>
</name>
</person-group>
<source>Malignant transformation of oral epithelial dysplasia: clinicopathological risk factors and outcome analysis in a retrospective cohort of 138 cases. Histopathology. 2011 Oct;59(4):733-40.</source>
<pub-id pub-id-type="pmid">21916948</pub-id>
<pub-id pub-id-type="doi">10.1111/j.1365-2559.2011.03938.x</pub-id>
</element-citation>
  </ref>
  <ref id="B5"><label>5</label>
    <element-citation>
      <person-group person-group-type="author">
        <name>
<surname>Kujan</surname>
<given-names>O</given-names>
</name><name>
<surname>Oliver</surname>
<given-names>RJ</given-names>
</name><name>
<surname>Khattab</surname>
<given-names>A</given-names>
</name><name>
<surname>Roberts</surname>
<given-names>SA</given-names>
</name><name>
<surname>Thakker</surname>
<given-names>N</given-names>
</name><name>
<surname>Sloan</surname>
<given-names>P</given-names>
</name>
</person-group>
<source>Evaluation of a new binary system of grading oral epithelial dysplasia for prediction of malignant transformation. Oral Oncol. 2006 Nov;42(10):987-93.</source>
<pub-id pub-id-type="pmid">16731030</pub-id>
<pub-id pub-id-type="doi">10.1016/j.oraloncology.2005.12.014</pub-id>
</element-citation>
  </ref>
  <ref id="B6"><label>6</label>
    <element-citation>
      <person-group person-group-type="author">
        <name>
<surname>Kulasekara</surname>
<given-names>KK</given-names>
</name><name>
<surname>Lukandu</surname>
<given-names>OM</given-names>
</name><name>
<surname>Neppelberg</surname>
<given-names>E</given-names>
</name><name>
<surname>Vintermyr</surname>
<given-names>OK</given-names>
</name><name>
<surname>Johannessen</surname>
<given-names>AC</given-names>
</name><name>
<surname>Costea</surname>
<given-names>DE</given-names>
</name>
</person-group>
<source>Cancer progression is associated with increased expression of basement membrane proteins in three-dimensional in vitro models of human oral cancer. Arch Oral Biol. 2009 Oct;54(10):924-31.</source>
<pub-id pub-id-type="pmid">19674736</pub-id>
<pub-id pub-id-type="doi">10.1016/j.archoralbio.2009.07.004</pub-id>
</element-citation>
  </ref>
  <ref id="B7"><label>7</label>
    <element-citation>
      <person-group person-group-type="author">
        <name>
<surname>Tringler</surname>
<given-names>B</given-names>
</name><name>
<surname>Grimm</surname>
<given-names>C</given-names>
</name><name>
<surname>Dudek</surname>
<given-names>G</given-names>
</name><name>
<surname>Horvat</surname>
<given-names>R</given-names>
</name><name>
<surname>Zeillinger</surname>
<given-names>R</given-names>
</name><name>
<surname>Hefler</surname>
<given-names>LA</given-names>
</name><name>
<surname>Kohlberger</surname>
<given-names>P</given-names>
</name>
</person-group>
<source>The lack of laminin-5 as a prognostic marker in low-grade cervical squamous intraepithelial lesions: correlation with clinical follow-up data. Int J Gynecol Pathol. 2007 Jan;26(1):89-94.</source>
<pub-id pub-id-type="pmid">17197903</pub-id>
<pub-id pub-id-type="doi">10.1097/01.pgp.0000225847.44374.6e</pub-id>
</element-citation>
  </ref>
  <ref id="B8"><label>8</label>
    <element-citation>
      <person-group person-group-type="author">
        <name>
<surname>Marangon Junior</surname>
<given-names>H</given-names>
</name><name>
<surname>Rocha</surname>
<given-names>VN</given-names>
</name><name>
<surname>Leite</surname>
<given-names>CF</given-names>
</name><name>
<surname>de Aguiar</surname>
<given-names>MC</given-names>
</name><name>
<surname>Souza</surname>
<given-names>PE</given-names>
</name><name>
<surname>Horta</surname>
<given-names>MC</given-names>
</name>
</person-group>
<source>Laminin-5 gamma 2 chain expression is associated with intensity of tumor budding and density of stromal myofibroblasts in oral squamous cell carcinoma. J Oral Pathol Med. 2014 Mar;43(3):199-204.</source>
<pub-id pub-id-type="pmid">24118289</pub-id>
<pub-id pub-id-type="doi">10.1111/jop.12121</pub-id>
</element-citation>
  </ref>
  <ref id="B9"><label>9</label>
    <element-citation>
      <person-group person-group-type="author">
        <name>
<surname>Nguyen</surname>
<given-names>CT</given-names>
</name><name>
<surname>Okamura</surname>
<given-names>T</given-names>
</name><name>
<surname>Morita</surname>
<given-names>KI</given-names>
</name><name>
<surname>Yamaguchi</surname>
<given-names>S</given-names>
</name><name>
<surname>Harada</surname>
<given-names>H</given-names>
</name><name>
<surname>Miki</surname>
<given-names>Y</given-names>
</name><name>
<surname>Izumo</surname>
<given-names>T</given-names>
</name><name>
<surname>Kayamori</surname>
<given-names>K</given-names>
</name><name>
<surname>Yamaguchi</surname>
<given-names>A</given-names>
</name><name>
<surname>Sakamoto</surname>
<given-names>K</given-names>
</name>
</person-group>
<source>LAMC2 is a predictive marker for the malignant progression of leukoplakia. J Oral Pathol Med. 2017 Mar;46(3):223-231.</source>
<pub-id pub-id-type="pmid">27529842</pub-id>
<pub-id pub-id-type="doi">10.1111/jop.12485</pub-id>
</element-citation>
  </ref>
  <ref id="B10"><label>10</label>
    <element-citation>
      <person-group person-group-type="author">
        <name>
<surname>Aparna</surname>
<given-names>M</given-names>
</name><name>
<surname>Rao</surname>
<given-names>L</given-names>
</name><name>
<surname>Kunhikatta</surname>
<given-names>V</given-names>
</name><name>
<surname>Radhakrishnan</surname>
<given-names>R</given-names>
</name>
</person-group>
<source>The role of MMP-2 and MMP-9 as prognostic markers in the early stages of tongue squamous cell carcinoma. J Oral Pathol Med. 2015 May;44(5):345-52.</source>
<pub-id pub-id-type="pmid">25212455</pub-id>
<pub-id pub-id-type="doi">10.1111/jop.12245</pub-id>
</element-citation>
  </ref>
  <ref id="B11"><label>11</label>
    <element-citation>
      <person-group person-group-type="author">
        <name>
<surname>Wu</surname>
<given-names>ZS</given-names>
</name><name>
<surname>Wu</surname>
<given-names>Q</given-names>
</name><name>
<surname>Yang</surname>
<given-names>JH</given-names>
</name><name>
<surname>Wang</surname>
<given-names>HQ</given-names>
</name><name>
<surname>Ding</surname>
<given-names>XD</given-names>
</name><name>
<surname>Yang</surname>
<given-names>F</given-names>
</name><name>
<surname>Xu</surname>
<given-names>XC</given-names>
</name>
</person-group>
<source>Prognostic significance of MMP-9 and TIMP-1 serum and tissue expression in breast cancer. Int J Cancer. 2008 May 1;122(9):2050-6.</source>
<pub-id pub-id-type="pmid">18172859</pub-id>
<pub-id pub-id-type="doi">10.1002/ijc.23337</pub-id>
</element-citation>
  </ref>
  <ref id="B12"><label>12</label>
    <element-citation>
      <person-group person-group-type="author">
        <name>
<surname>Jumper</surname>
<given-names>C</given-names>
</name><name>
<surname>Cobos</surname>
<given-names>E</given-names>
</name><name>
<surname>Lox</surname>
<given-names>C</given-names>
</name>
</person-group>
<source>Determination of the serum matrix metalloproteinase-9 (MMP-9) and tissue inhibitor of matrix metalloproteinase-1 (TIMP-1) in patients with either advanced small-cell lung cancer or non-small-cell lung cancer prior to treatment. Respir Med. 2004 Feb;98(2):173-7.</source>
<pub-id pub-id-type="pmid">14971882</pub-id>
<pub-id pub-id-type="doi">10.1016/j.rmed.2003.08.014</pub-id>
</element-citation>
  </ref>
  <ref id="B13"><label>13</label>
    <element-citation>
      <person-group person-group-type="author">
        <name>
<surname>Cho</surname>
<given-names>YB</given-names>
</name><name>
<surname>Lee</surname>
<given-names>WY</given-names>
</name><name>
<surname>Song</surname>
<given-names>SY</given-names>
</name><name>
<surname>Shin</surname>
<given-names>HJ</given-names>
</name><name>
<surname>Yun</surname>
<given-names>SH</given-names>
</name><name>
<surname>Chun</surname>
<given-names>HK</given-names>
</name>
</person-group>
<source>Matrix metalloproteinase-9 activity is associated with poor prognosis in T3-T4 node-negative colorectal cancer. Hum Pathol. 2007 Nov;38(11):1603-10.</source>
<pub-id pub-id-type="pmid">17669467</pub-id>
<pub-id pub-id-type="doi">10.1016/j.humpath.2007.03.018</pub-id>
</element-citation>
  </ref>
  <ref id="B14"><label>14</label>
    <element-citation>
      <person-group person-group-type="author">
        <name>
<surname>Tamamura</surname>
<given-names>R</given-names>
</name><name>
<surname>Nagatsuka</surname>
<given-names>H</given-names>
</name><name>
<surname>Siar</surname>
<given-names>CH</given-names>
</name><name>
<surname>Katase</surname>
<given-names>N</given-names>
</name><name>
<surname>Naito</surname>
<given-names>I</given-names>
</name><name>
<surname>Sado</surname>
<given-names>Y</given-names>
</name><name>
<surname>Nagai</surname>
<given-names>N</given-names>
</name>
</person-group>
<source>Comparative analysis of basal lamina type IV collagen α chains, matrix metalloproteinases-2 and -9 expressions in oral dysplasia and invasive carcinoma. Acta Histochem. 2013 Mar;115(2):113-9.</source>
<pub-id pub-id-type="pmid">22694915</pub-id>
<pub-id pub-id-type="doi">10.1016/j.acthis.2012.05.001</pub-id>
</element-citation>
  </ref>
  <ref id="B15"><label>15</label>
    <element-citation>
      <person-group person-group-type="author">
        <name>
<surname>Shenoi</surname>
<given-names>R</given-names>
</name><name>
<surname>Devrukhkar</surname>
<given-names>V</given-names>
</name><name>
<surname>Chaudhuri</surname>
</name><name>
<surname>Sharma</surname>
<given-names>BK</given-names>
</name><name>
<surname>Sapre</surname>
<given-names>SB</given-names>
</name><name>
<surname>Chikhale</surname>
<given-names>A</given-names>
</name>
</person-group>
<source>Demographic and clinical profile of oral squamous cell carcinoma patients: a retrospective study. Indian J Cancer. 2012 Jan-Mar;49(1):21-6.</source>
<pub-id pub-id-type="pmid">22842164</pub-id>
<pub-id pub-id-type="doi">10.4103/0019-509X.98910</pub-id>
</element-citation>
  </ref>
  <ref id="B16"><label>16</label>
    <element-citation>
      <person-group person-group-type="author">
        <name>
<surname>Dost</surname>
<given-names>F</given-names>
</name><name>
<surname>Lê Cao</surname>
<given-names>KA</given-names>
</name><name>
<surname>Ford</surname>
<given-names>PJ</given-names>
</name><name>
<surname>Farah</surname>
<given-names>CS</given-names>
</name>
</person-group>
<source>A retrospective analysis of clinical features of oral malignant and potentially malignant disorders with and without oral epithelial dysplasia. Oral Surg Oral Med Oral Pathol Oral Radiol. 2013 Dec;116(6):725-33.</source>
<pub-id pub-id-type="pmid">24144993</pub-id>
<pub-id pub-id-type="doi">10.1016/j.oooo.2013.08.005</pub-id>
</element-citation>
  </ref>
  <ref id="B17"><label>17</label>
    <element-citation>
      <person-group person-group-type="author">
        <name>
<surname>Hirashima</surname>
<given-names>K</given-names>
</name><name>
<surname>Iyama</surname>
<given-names>K</given-names>
</name><name>
<surname>Baba</surname>
<given-names>Y</given-names>
</name><name>
<surname>Honda</surname>
<given-names>Y</given-names>
</name><name>
<surname>Sado</surname>
<given-names>Y</given-names>
</name><name>
<surname>Ninomiya</surname>
<given-names>Y</given-names>
</name><name>
<surname>Watanabe</surname>
<given-names>M</given-names>
</name><name>
<surname>Takamori</surname>
<given-names>H</given-names>
</name><name>
<surname>Beppu</surname>
<given-names>T</given-names>
</name><name>
<surname>Baba</surname>
<given-names>H</given-names>
</name>
</person-group>
<source>Differential expression of basement membrane type IV collagen α2 and α6 chains as a prognostic factor in patients with extrahepatic bile duct carcinoma. J Surg Oncol. 2013 Mar;107(4):402-7.</source>
<pub-id pub-id-type="pmid">22927259</pub-id>
<pub-id pub-id-type="doi">10.1002/jso.23225</pub-id>
</element-citation>
  </ref>
  <ref id="B18"><label>18</label>
    <element-citation>
      <person-group person-group-type="author">
        <name>
<surname>Imura</surname>
<given-names>J</given-names>
</name><name>
<surname>Uchida</surname>
<given-names>Y</given-names>
</name><name>
<surname>Nomoto</surname>
<given-names>K</given-names>
</name><name>
<surname>Ichikawa</surname>
<given-names>K</given-names>
</name><name>
<surname>Tomita</surname>
<given-names>S</given-names>
</name><name>
<surname>Iijima</surname>
<given-names>T</given-names>
</name><name>
<surname>Fujimori</surname>
<given-names>T</given-names>
</name>
</person-group>
<source>Laminin-5 is a biomarker of invasiveness in cervical adenocarcinoma. Diagn Pathol. 2012 Aug 17;7:105..</source>
<pub-id pub-id-type="pmid">22898004</pub-id>
<pub-id pub-id-type="pmcid">PMC 3520835</pub-id>
<pub-id pub-id-type="doi">10.1186/1746-1596-7-105</pub-id>
</element-citation>
  </ref>
  <ref id="B19"><label>19</label>
    <element-citation>
      <person-group person-group-type="author">
        <name>
<surname>Zargaran</surname>
<given-names>M</given-names>
</name><name>
<surname>Eshghyar</surname>
<given-names>N</given-names>
</name><name>
<surname>Vaziri</surname>
<given-names>PB</given-names>
</name><name>
<surname>Mortazavi</surname>
<given-names>H</given-names>
</name>
</person-group>
<source>Immunohistochemical evaluation of type IV collagen and laminin-332 γ2 chain expression in well-differentiated oral squamous cell carcinoma and oral verrucous carcinoma: a new recommended cut-off. J Oral Pathol Med. 2011 Feb;40(2):167-73.</source>
<pub-id pub-id-type="pmid">21158930</pub-id>
<pub-id pub-id-type="doi">10.1111/j.1600-0714.2010.00983.x</pub-id>
</element-citation>
  </ref>
  <ref id="B20"><label>20</label>
    <element-citation>
      <person-group person-group-type="author">
        <name>
<surname>Gasparoni</surname>
<given-names>A</given-names>
</name><name>
<surname>Della Casa</surname>
<given-names>M</given-names>
</name><name>
<surname>Milillo</surname>
<given-names>L</given-names>
</name><name>
<surname>Lorenzini</surname>
<given-names>G</given-names>
</name><name>
<surname>Rubini</surname>
<given-names>C</given-names>
</name><name>
<surname>Urso</surname>
<given-names>R</given-names>
</name><name>
<surname>Lo Muzio</surname>
<given-names>L</given-names>
</name>
</person-group>
<source>Prognostic value of differential expression of Laminin-5 gamma2 in oral squamous cell carcinomas: correlation with survival. Oncol Rep. 2007 Oct;18(4):793-800.</source>
<pub-id pub-id-type="pmid">17786338</pub-id>
</element-citation>
  </ref>
  <ref id="B21"><label>21</label>
    <element-citation>
      <person-group person-group-type="author">
        <name>
<surname>Garg</surname>
<given-names>M</given-names>
</name><name>
<surname>Kanojia</surname>
<given-names>D</given-names>
</name><name>
<surname>Okamoto</surname>
<given-names>R</given-names>
</name><name>
<surname>Jain</surname>
<given-names>S</given-names>
</name><name>
<surname>Madan</surname>
<given-names>V</given-names>
</name><name>
<surname>Chien</surname>
<given-names>W</given-names>
</name><name>
<surname>Sampath</surname>
<given-names>A</given-names>
</name><name>
<surname>Ding</surname>
<given-names>LW</given-names>
</name><name>
<surname>Xuan</surname>
<given-names>M</given-names>
</name><name>
<surname>Said</surname>
<given-names>JW</given-names>
</name><name>
<surname>Doan</surname>
<given-names>NB</given-names>
</name><name>
<surname>Liu</surname>
<given-names>LZ</given-names>
</name><name>
<surname>Yang</surname>
<given-names>H</given-names>
</name><name>
<surname>Gery</surname>
<given-names>S</given-names>
</name><name>
<surname>Braunstein</surname>
<given-names>GD</given-names>
</name><name>
<surname>Koeffler</surname>
<given-names>HP</given-names>
</name>
</person-group>
<source>Laminin-5γ-2 (LAMC2) is highly expressed in anaplastic thyroid carcinoma and is associated with tumor progression, migration, and invasion by modulating signaling of EGFR. J Clin Endocrinol Metab. 2014 Jan;99(1):E62-72.</source>
<pub-id pub-id-type="pmid">24170107</pub-id>
<pub-id pub-id-type="pmcid">PMC 3879679</pub-id>
<pub-id pub-id-type="doi">10.1210/jc.2013-2994</pub-id>
</element-citation>
  </ref>
  <ref id="B22"><label>22</label>
    <element-citation>
      <person-group person-group-type="author">
        <name>
<surname>Frank</surname>
<given-names>DE</given-names>
</name><name>
<surname>Carter</surname>
<given-names>WG</given-names>
</name>
</person-group>
<source>Laminin 5 deposition regulates keratinocyte polarization and persistent migration. J Cell Sci. 2004 Mar 15;117(Pt 8):1351-63.</source>
<pub-id pub-id-type="pmid">14996912</pub-id>
<pub-id pub-id-type="doi">10.1242/jcs.01003</pub-id>
</element-citation>
  </ref>
  <ref id="B23"><label>23</label>
    <element-citation>
      <person-group person-group-type="author">
        <name>
<surname>Georgescu</surname>
<given-names>EF</given-names>
</name><name>
<surname>Mogoantă</surname>
<given-names>SŞ</given-names>
</name><name>
<surname>Costache</surname>
<given-names>A</given-names>
</name><name>
<surname>Pârvănescu</surname>
<given-names>V</given-names>
</name><name>
<surname>Totolici</surname>
<given-names>BD</given-names>
</name><name>
<surname>Pătraşcu</surname>
<given-names>Ş</given-names>
</name><name>
<surname>Stănescu</surname>
<given-names>C</given-names>
</name>
</person-group>
<source>The assessment of matrix metalloproteinase-9 expression and angiogenesis in colorectal cancer. Rom J Morphol Embryol. 2015;56(3):1137-44.</source>
<pub-id pub-id-type="pmid">26662150</pub-id>
</element-citation>
  </ref>
  <ref id="B24"><label>24</label>
    <element-citation>
      <person-group person-group-type="author">
        <name>
<surname>Andisheh-Tadbir</surname>
<given-names>A</given-names>
</name><name>
<surname>Mardani</surname>
<given-names>M</given-names>
</name><name>
<surname>Pourshahidi</surname>
<given-names>S</given-names>
</name><name>
<surname>Nezarati</surname>
<given-names>K</given-names>
</name><name>
<surname>Bahadori</surname>
<given-names>P</given-names>
</name>
</person-group>
<source>Prognostic value of matrix metalloproteinase-9 expression in oral squamous cell carcinoma and its association with angiogenesis. J Clin Exp Dent. 2016 Apr 1;8(2): e130-5.</source>
<pub-id pub-id-type="pmid">27034751</pub-id>
<pub-id pub-id-type="pmcid">PMC 4808306</pub-id>
<pub-id pub-id-type="doi">10.4317/jced.52712</pub-id>
</element-citation>
  </ref>
  </ref-list>
</back>
</article>